MC

Molecular Cancer Therapeutics

Molecular Cancer Therapeutics publishes articles on the discovery and preclinical development of novel therapeutic agents for oncology, preclinical studies of approved therapeutics, mechanisms of drug action, mechanism of drug resistance, biomarkers of drug response, novel models and technologies, and occasional drug toxicity mechanisms.

Looking to publish in Molecular Cancer Therapeutics? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Try Livewrite Now
Subject Oncology
Impact Factor 5.5
Quartile Q1
Open Access Type Closed
ISSN 1535-7163
eISSN 1538-8514
Invitation Only No
Cost Range Publication involves a base publication fee and an additional fee for each display item; authors without financial support may apply for a waiver of the fixed publication fee at submission.

Submission Instructions

Molecular Cancer Therapeutics accepts the following article types. Click on an article type to view submission instructions.

Meta-Analysis

Cover Letter Cover letter is strongly encouraged but not required.
Abstract Abstract requirements are not specified.
Manuscript No strict length restriction is imposed on initial submissions, and the Methods section is excluded when calculating manuscript length. Manuscript must be arranged in the following order: title page, text and references, tables, figure legends, and figures. The title page must include the conflict of interest disclosure statement, word count, total number of figures and tables, and the exact data-responsibility statement from at least one named author, and any use of generative AI for manuscript preparation must be declared in the acknowledgments section.
References References must be numbered in order of first mention in the text, cited in the text by number only, and list all authors if there are 6 or fewer or the first 6 followed by "et al." if there are more than 6.
Figures & Tables For initial submission, each figure should be presented together with its legend in sequence, ideally embedded near its first callout or on the same page as the legend, while supplementary files must be uploaded separately. Each figure must have a legend with a short title sentence and description, multi-panel figures must have labeled panels described in the legend, and figure legends must include the number of technical and biological replicates.
Reformat to Molecular Cancer Therapeutics using Livewrite Premium

Systematic Reviews

Cover Letter Cover letter is strongly encouraged for initial submission. Cover letter must describe how any associated manuscript is related to the current submission.
Abstract An abstract is required.
Manuscript No strict length restriction is imposed on initial submissions, and the Methods section is excluded when calculating manuscript length. Manuscript must be arranged in the order of title page, text and references, tables, figure legends, and figures. Title page must include the conflict of interest disclosure statement, word count, and total number of figures and tables, and any use of generative artificial intelligence to assist manuscript preparation must be declared in the acknowledgments section.
References References must be numbered in the order of first mention in the text and cited in the text using only the assigned number. For references with more than 6 authors, list the first 6 authors followed by "et al.," and for references with 6 or fewer authors, list all authors.
Figures & Tables For initial submission, each figure should be presented together with its legend in sequential order either embedded near its first callout or on the same page, while supplementary files must be uploaded separately. Tables must be numbered with Arabic numerals, and each figure must include a legend with a short title sentence followed by a description of the figure and data shown.
Reformat to Molecular Cancer Therapeutics using Livewrite Premium

Original Research

Cover Letter Cover letter is strongly encouraged for initial submission. Cover letter must describe how any associated manuscript is related to the current submission.
Abstract An abstract is required.
Manuscript No strict length restriction is imposed for initial submissions, and the Methods section is excluded when calculating manuscript length. Manuscript must be arranged in the following order: title page, text and references, tables, figure legends, and figures. Original Research articles must include a Data Availability subsection at the end of the Materials and Methods or Methods section, a Code Availability Statement when custom code was used, and declarations of any generative AI assistance in the manuscript.
References References must be numbered in order of first mention, cited in text by number only, and list all authors if there are 6 or fewer or the first 6 followed by "et al." if there are more than 6.
Figures & Tables For initial submission, each figure should be presented together with its legend in sequential order, ideally embedded near its first callout, while supplementary data must be uploaded separately. Each figure must have a legend with a short title sentence and description, figures and tables must be cited in sequential order, and figure legends must include the numbers of technical and biological replicates.
Reformat to Molecular Cancer Therapeutics using Livewrite Premium

Recent Publications

Characterization of T Cell Engaging Bispecific Antibodies and Combination Therapies with a High-Throughput Multiparametric Automated Assay and Data Analysis Platform

Josefa dela Cruz Chuh, Sagana Anifa, Eric Torres, Michela Mirenda, Alice Munaretto, Margherita di Somma, Maria Elisa. Perico, Filippo Andreetta, Hok Seon Kim, Christoph Spiess, Fatima Raezelle. Javier, Eric Janezic, Shirley Ng Palace, Kevin Walsh, Mercedesz Balazs, Katherine R. Kozak, Christopher C. Kemball

10.1158/1535-7163.mct-25-1360
View Publication

Preclinical response of uveal melanomas to the velcrin compound, BAY 2666605

Kristýna Kotýnková, Sawyer Andersen, Daniel Denney, Gizem Karsli Uzunbas, Miles Burri, Xiaoyun Wu, Bethany Kaplan, Rizwan Haq, Matthew Meyerson, Heidi Greulich

10.1158/1535-7163.mct-25-1473
View Publication

A whole genomic CRISPR-Cas9 screen identifies the amino acid transporter SLC43A1 (LAT3) as a major determinant of oxaliplatin sensitivity in colorectal cancer cells

Nisha R. Pawar, Heidi M. Wade, Zoe Jackson, Nisha Poungpeth, Allison V. Mitchell, Connor P. Jewell, Dalen Chan, Pedro J. Batista, Robert W. Robey, Lisa M. Jenkins, Michael M. Gottesman

10.1158/1535-7163.mct-25-0508
View Publication

Suppression of AKT Activation Through LZK Inhibition Limits Tumor Growth in Esophageal and Head and Neck Cancers

Meghri Katerji, Maxine R. Rubin, Eric Lindberg, Pedro Torres-Ayuso, Aamna Siddiqui, Amy L. Funk, Katherine Nyswaner, Carolyn C. Woodroofe, Sarah Wolfe, Zoe C. Edwards, Eleanor W. Trotter, Erkan Baloglu, Ivan Ahel, Anna A. Marusiak, Alexandra Newton, Raul E. Cachau, Kiranya Arnold, Rolf E. Swenson, John Brognard

10.1158/1535-7163.mct-25-1042
View Publication

Selected Articles from This Issue

-

10.1158/1535-7163.mct-25-6-hi
View Publication

Frequently asked questions

How long does it take to publish?

For qualifying AACR Member authors, the time from completion of submission to the first decision after external peer review is targeted not to exceed 60 days.

Reformat to Molecular Cancer Therapeutics using Livewrite Premium

Is a cover letter required?

Authors are strongly encouraged to upload a cover letter for initial submission.

Reformat to Molecular Cancer Therapeutics using Livewrite Premium

What are the publication costs?

Publication involves a base publication fee and an additional fee for each display item; authors without financial support may apply for a waiver of the fixed publication fee at submission.

Reformat to Molecular Cancer Therapeutics using Livewrite Premium

Research Topics

Cancer, Hypoxia, and Metabolism Cancer-related Molecular Pathways Monoclonal and Polyclonal Antibodies Research Cancer Genomics and Diagnostics HER2/EGFR in Cancer Research Lung Cancer Treatments and Mutations Cancer Research and Treatments PI3K/AKT/mTOR signaling in cancer Ubiquitin and proteasome pathways Protein Degradation and Inhibitors RNA modifications and cancer Cancer Treatment and Pharmacology Cancer therapeutics and mechanisms Microtubule and mitosis dynamics DNA Repair Mechanisms Cancer Mechanisms and Therapy Advanced Breast Cancer Therapies Peptidase Inhibition and Analysis Epigenetics and DNA Methylation Cell death mechanisms and regulation Histone Deacetylase Inhibitors Research Colorectal Cancer Treatments and Studies Cancer Cells and Metastasis PARP inhibition in cancer therapy CAR-T cell therapy research

Related Journals

MT
Molecular Therapy Oncology CELL PRESS
AO
Annals of Oncology Elsevier BV
Ca
Cancers Multidisciplinary Digital Publishing Institute
Ne
Neuro-Oncology Oxford University Press
JG
JCO Global Oncology LIPPINCOTT WILLIAMS & WILKINS
RA
Radiotherapy and Oncology Elsevier BV